CIK 0001842295 · Non-accelerated filer<br>Emerging growth company
Maze Therapeutics, Inc.
Sign in to watch- Ticker
- MAZE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 6508505070
- Business address
- 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,785,701
- in 13 filings, $4.6M under 10b5-1 plans
Net −$5,785,701. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-11-19 | HOMCY CHARLES J Director | Other acquisition | +1,489 | 31,113 | ||
| 2025-11-04 | Third Rock Ventures IV, L.P. 10% owner | Other disposition | −1,600,000 | 4,473,958 | ||
| 2025-10-23 | HOMCY CHARLES J Director | Gift | −28,423 | 29,624 | ||
| 2025-10-06 | Hoppenot Herve Director | Grant or award · Stock Option (Right to Buy) | +36,000 | 36,000 | ||
| 2025-09-22 | Bachrodt Amy SVP, Finance | Grant or award · Restricted Stock Units | +22,000 | 22,000 | ||
| 2025-09-22 | Bernstein Harold President, R&D & CMO | Grant or award · Restricted Stock Units | +40,000 | 40,000 | ||
| 2025-09-22 | Dandekar Atul CSBO | Grant or award · Restricted Stock Units | +25,000 | 25,000 | ||
| 2025-09-22 | Kathiresan Sekar Director | Grant or award · Stock Option (Right to Buy) | +18,000 | 18,000 | ||
| 2025-09-22 | Andrews Nancy C Director | Grant or award · Stock Option (Right to Buy) | +18,000 | 18,000 | ||
| 2025-09-22 | Courtney Phillips GC and Corp. Secretary | Grant or award · Restricted Stock Units | +22,000 | 22,000 | ||
| 2025-09-22 | Coloma Jason V Chief Executive Officer | Grant or award · Restricted Stock Units | +100,000 | 100,000 | ||
| 2025-09-22 | Exter Neil Director | Grant or award · Stock Option (Right to Buy) | +18,000 | 18,000 | ||
| 2025-09-22 | Sohn Catherine A. Director | Grant or award · Stock Option (Right to Buy) | +18,000 | 18,000 | ||
| 2025-09-22 | Lim Jonathan E Director | Grant or award · Stock Option (Right to Buy) | +18,000 | 18,000 | ||
| 2025-09-22 | SPIEGELMAN DANIEL K Director | Grant or award · Stock Option (Right to Buy) | +18,000 | 18,000 | ||
| 2025-09-22 | SCHELLER RICHARD H Director | Grant or award · Stock Option (Right to Buy) | +18,000 | 18,000 | ||
| 2025-09-22 | HOMCY CHARLES J Director | Grant or award · Stock Option (Right to Buy) | +18,000 | 18,000 | ||
| 2025-09-15 | SCHELLER RICHARD H Director | Sale | −20,744 | $22.37 | $464K | 0 |
| 2025-09-02 | Tahir Misbah Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +325,000 | 325,000 | ||
| 2025-08-17 | Exter Neil Director | Grant or award · Stock Option (Right to Buy) | +16,000 | 16,000 |
Page 12 of 14 · 267 trades